NORTHERN IRELAND
Ireland can help mitigate supply chain challenges. As part of the UK Life Science Super Cluster,
Northern Ireland has been recognised as a region with high growth opportunities in diagnostics, data integration, digital health, wearables, and advanced pharmaceutical delivery systems. Its vibrant cluster of 250+ businesses, which are a mix of international investors and indigenous companies such as Almac and Randox, continue to grow and prosper in the region. In fact, some of the world’s leading medical and life science companies have invested in Northern Ireland in recent years, including Terumo, Stryker, and TEVA Pharmaceutical Industries – a testament to the region’s compelling proposition. The cluster also includes highly innovative small and medium-sized enterprises, including Axial3D, Armstrong Medical, Cirdan, Cumulus Neuroscience, Sonrai Analytics, Neurovalens, TruCorp, and ProAxsis.
Future-proofing Northern Ireland’s Life and Health Sciences Ecosystem Both the national and local governments are committed to the development and advancement of life and health sciences in Northern Ireland. Recent government investment includes £1.3 billion through City and Growth deals, with over £140 million earmarked for future opportunities for healthcare in the region. These investments will create global centres of
innovation and provide opportunities for businesses located both in and outside of Northern Ireland to collaborate and tap into the world-leading expertise of the region’s universities to create breakthrough technologies, products, and services.
Northern Ireland’s life and health sciences
ecosystem was further strengthened in 2021 with the formation of the Health Innovation Research Alliance Northern Ireland (HIRANI). HIRANI is focused on driving collaboration by maintaining a clear and strategic direction and acting as a single voice for the sector with a focus on promoting life and health sciences capabilities in Northern Ireland.
Unique access to Great Britain (GB) and the EU markets Following the UK’s exit from the European Union (EU), agreements made between both jurisdictions through the Withdrawal Agreement (Northern Ireland Protocol and Windsor Framework) means that Northern Ireland continues to have full market access to GB and the EU. This means that Northern Ireland is a gateway
for the sale of goods to two of the world’s largest markets and the only place in the world where businesses can operate free from customs declarations, rules of origin certificates, and non-tariff barriers on the sale of goods to both GB and the EU. With Northern Ireland maintaining regulatory
alignment with the EU on goods, medical device and diagnostic manufacturers based in Northern Ireland can service GB and EU markets, recalibrate supply chains and design, develop and sell products more easily. Built on a rich history of science and medicine,
Northern Ireland offers solutions for life sciences companies to take their products at pace, from research to clinical trials – through development, manufacturing, and distribution. With government support, university innovation, manufacturing excellence, a cluster of thriving life and health science companies, and unique market access, Northern Ireland is truly a location for the future of life and health sciences. Find out more information on the life and health sciences sector in Northern Ireland:
www.investni. com/life-and-health-sciences
MEDICA 2023 UKHEALTHCARE P A VILION. COM 21
Queen’s University Belfast – Precision Medicine Centre
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
